Phase 2 Alzheimer's Disease Trial, Recruiting NCT07143734 Sponsor: Chinese University of Hong Kong Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT07143734
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who have been clinically diagnosed with early-stage Alzheimer's Disease, specifically at stages 2 to 6a as measured by a standard assessment tool called the Functional Assessment Staging Test
  • People whose ability to agree to take part in research has been assessed and confirmed by an experienced specialist doctor in older adult care
  • People aged between 60 and 90 years old
  • People who are able to give their agreement to take part with some assistance, where a family caregiver is present to witness and sign alongside them

Who may not be able to join:

  • People who are not able to understand Chinese
  • People who have been assessed as not having the mental capacity to agree to take part in research
  • People who are unable to sit or remain still for 30 minutes
  • People who do not have a family caregiver available to answer questionnaires on their behalf
  • People with a dependence on alcohol or other substances
  • People with major neurological conditions, including a brain tumour, a brain aneurysm, any metal implants in the brain, a bleeding disorder such as haemophilia, or a history of blood clots (thrombosis)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Timothy Chi Yui Kwok, PhD, Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese UNiversity of Hong Kong

Phone: (+852) 62087351

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
21 July 2025
Est. completion
1 April 2026

Where this trial is recruiting

Hong Kong

Primary endpoints

Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale score.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov